Published in Drug Week, September 9th, 2005
The revised efficacy analysis is consistent with the analysis upon which a recent approval of another IV iron product was based. These modifications will result in additional patients being enrolled in the ferumoxytol chronic kidney disease (CKD) efficacy studies and will involve the re-design of the hemodialysis protocol currently under way.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week